title: Gaucher disease: studies of phenotype, molecular diagnosis and treatment.
abstract: This report summarizes the results on 39 patients with Gaucher disease who have been genotyped, evaluated, and/or followed at this center. Mutation analysis for 4 common mutations; N370S, L444P, 84gg and IVS2 (+1), was performed for all patients. Mutation analysis identified both mutant alleles in 69% and at least one mutant allele in 90% of all chromosomes. This study group of 39 patients included 32 type 1, four type 2 and three type 3 patients. We include the details of the clinical course of two patients with Gaucher disease treated with enzyme replacement therapy (ERT). One patient with chronic neuronopathic Gaucher disease has been treated with enzyme replacement therapy (ERT) at a dose of 60 U/kg every 2 weeks since 2.5 years of age and has shown no progression of neurologic involvement. A second patient with non-neuronopathic Gaucher disease has demonstrated an unusually delayed response to ERT. No clinical response was noted following 17 months of treatment at 60 U/kg every 2 weeks. Only after the dose was increased to 60 U/kg every week was a clinical response evident. Response to treatment at 15 U/kg every 2 weeks was variable in the four type 1 patients treated at the lower dose. In two of these patients with identical genotypes, one patient demonstrated a positive clinical response to low dose treatment while the other patient did not.
authors: Department of Human Genetics, University of Pittsburgh, PA 15261, USA.
authors: E O
authors: EO
authors: Rice
authors: T E
authors: TE
authors: Mifflin
authors: S
authors: S
authors: Sakallah
authors: R E
authors: RE
authors: Lee
authors: C A
authors: CA
authors: Sansieri
authors: J A
authors: JA
authors: Barranger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002490:Central Nervous System / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D005962:Glucosylceramidase / Q000235:genetics* / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007585:Jews; D008297:Male; D008875:Middle Aged; D009154:Mutation; D013154:Spleen / Q000473:pathology; D044465:White People
chemical_list: D005962:Glucosylceramidase